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Abstract
Objective: Female genital tract secretions inhibit E. coli ex vivo and the activity may prevent colonization and provide a
biomarker of a healthy microbiome. We hypothesized that high E. coli inhibitory activity would be associated with a
Lactobacillus crispatus and/or jensenii dominant microbiome and differ from that of women with low inhibitory activity.
Study Design: Vaginal swab cell pellets from 20 samples previously obtained in a cross-sectional study of near-term
pregnant and non-pregnant healthy women were selected based on having high (.90% inhibition) or low (,20%
inhibition) anti-E. coli activity. The V6 region of the 16S ribosomal RNA gene was amplified and sequenced using the
Illumina HiSeq 2000 platform. Filtered culture supernatants from Lactobacillus crispatus, Lactobacillus iners, and Gardnerella
vaginalis were also assayed for E. coli inhibitory activity.
Results: Sixteen samples (10 with high and 6 with low activity) yielded evaluable microbiome data. There was no difference
in the predominant microbiome species in pregnant compared to non-pregnant women (n = 8 each). However, there were
significant differences between women with high compared to low E. coli inhibitory activity. High activity was associated
with a predominance of L. crispatus (p,0.007) and culture supernatants from L. crispatus exhibited greater E. coli inhibitory
activity compared to supernatants obtained from L. iners or G. vaginalis. Notably, the E. coli inhibitory activity varied among
different strains of L. crispatus.
Conclusion: Microbiome communities with abundant L. crispatus likely contribute to the E. coli inhibitory activity of vaginal
secretions and efforts to promote this environment may prevent E. coli colonization and related sequelae including preterm
birth.
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Introduction
Preterm birth is a major health problem affecting 12.3% of live
births and is a major cause of neonatal mortality [1,2]. Escherichia
coli (E. coli) has been associated with preterm birth [3], is among
the leading cause of neonatal sepsis in extremely low birth weight
neonates [4], and is the leading cause of early-onset neonatal sepsis
and meningitis [5]. Similarly, bacterial vaginosis (BV), a dysbiotic
condition characterized by the replacement of a Lactobacillus
crispatus (L. crispatus) predominant microbiome with anaerobic
species [6,7], has also been linked to an increased risk of preterm
birth, although treatment with antibiotics in late pregnancy was
ineffective [8–10]. These findings indicate that the vaginal
microbiome plays an important role in adverse pregnancy
outcomes.
Recent studies suggest that the vaginal microbiome may be
linked to soluble mucosal defense. Specifically, genital tract
secretions have been consistently shown to possess in vitro
inhibitory activity against E. coli [11–15]. This activity, which
may reflect contributions from the host innate immune mediators
such as defensins as well as from microbiota, may be critical during
pregnancy and prevent dysbiotic vaginal colonization and
ascending infection. Earlier studies showed that the E. coli
inhibitory activity was reduced among non-pregnant women with
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BV and was restored following successful treatment with
metronidazole [11]. In a recent cross sectional study, genital tract
secretions obtained by vaginal swabs from near term healthy
pregnant women were found to have significantly higher
inhibitory activity against E. coli that was inversely correlated with
E. coli vaginal colonization [12]. A separate study using
cervicovaginal lavage (CVL) samples from healthy non-pregnant
women suggested that the inhibitory activity may be mediated, at
least in part, by soluble proteins secreted by lactobacilli [15]. Using
biochemical techniques including mass spectrometry, four Lacto-
bacillus proteins (three originally described as proteins of L. crispatus
and one of L. jensenii) were present exclusively in CVL samples with
high (.90% inhibitory activity), but not in samples with low
activity (,20%). These proteins included the S-layer protein, a
bacterial surface layer protein, and a cell separation protein for L.
crispatus and adhesion exoprotein for L. jensenii [15].
Building on this background, the current study was designed to
further evaluate the link between E. coli inhibitory activity and the
vaginal microbiome and to test the hypothesis that high E. coli
inhibitory activity would be associated with healthy Lactobacillus
species dominant microbiome whereas low activity would be
associated with a more diverse microbiome. Utilizing samples
previously obtained from healthy near term pregnant and non-
pregnant women, we also tested the hypothesis that pregnancy
would alter the microbiome, as suggested in a prior study [16]. A
subset of samples were selected from 10 pregnant and 10 non-
pregnant women and within each cohort, five were selected for
high inhibitory activity (defined as .90% reduction in number of
E. coli colony forming units [cfu]) and five with low activity
(defined as ,20% reduction in cfu).
Materials and Methods
Participants and Sample Collection
The parent study was described previously in detail [12].
Briefly, healthy pregnant women were recruited between 35 and
37 weeks of gestation and healthy non-pregnant were recruited
during a routine gynecologic visit. Vaginal swabs were collected to
measure soluble immune mediators and endogenous E. coli
inhibitory activity. Following approval from the Montefiore
Medical Center Internal Review Board, all women gave written
informed consent. For this sub-study, vaginal swab pellets from 10
pregnant women between 35 and 37 weeks of gestation and 10
healthy non-pregnant women (5 with E. coli inhibitory activity .
90% and 5 with activity ,20% within each group) were selected
and analyzed in a blinded manner for the vaginal microbiome.
None of the participants had clinical BV using Amsel’s criteria
[17].
Vaginal swabs were placed in a 1.5 mL sterile eppendorf tube
that was pre-filled with 0.5 mL of sterile normal saline, placed on
ice, and processed within 6 hours of collection. The sample was
vortexed and clarified by centrifugation at 2000 rpm for 7 minutes
at 4uC and the cell pellets were re-suspended in 200 mL of
phosphate buffered solution (PBS) and stored at 280uC until used
for the microbiome analysis. The supernatants were divided into
aliquots and used to measure E. coli inhibitory activity as well as
concentrations of immune mediators [12]. The Internal Review
Board of Albert Einstein College of Medicine approved the parent
study; all participants signed informed consent and only subjects
who agreed that samples could be used for future studies were
included.
DNA Extraction and Amplification
Relatively low-cycle amplification and next generation sequenc-
ing (NGS) on the Illumina HiSeq2000 platform, in conjunction
with pplacer software was used to analyze the bacterial compo-
sition of vaginal samples. DNA for sequencing was extracted from
pelleted cells by incubating 150 ml of sample in 250 ml of
proteinase K digestion cocktail containing 1% sodium laureth-12
sulfate at 55uC for 2 hours heated to 95u610 minutes and then the
DNA was precipitated in a 0.825 M ammonium acetate/ethanol
(AAE) solution, pelleted by centrifugation and re-suspended in TE
(10 mM Tris, pH 8.0, 0.1 mM EDTA), as described previously
[18–20]. The V6 region of 16S rRNA genes were amplified in an
ABI 9700 Thermal Cycler (Life, Carlsbad, CA) using HotStart-IT
FideliTaq DNA Polymerase (Affymetrix, Santa Clara, CA) and
50 ng of template DNA in a total volume of 50 ml. Reaction
parameters included initial denaturation at 94uC for 2 min,
followed with 30 cycles of denaturation at 94uC for 30 seconds,
annealing at 60uC for 30 seconds, and extension at 68uC for
30 seconds; and a final extension at 68uC for 5 min. Sense target
primers contained unique 8-bp Hamming DNA barcodes [21],
which allowed for the identification of reads from each sample.
Successfully amplified DNA from all samples was pooled, purified
and isolated using gel electrophoresis and electroelution. Following
quality control and library preparation, DNA was sequenced on
an Illumina HiSeq 2000 using a paired-end protocol yielding 100
base pairs of sequence in each direction. Raw sequences were
joined (using eautils’ fastq-join), processed to remove chimeras
(using uchime), and low quality reads and nucleotides, and
assigned to their sample of origin by demultiplexing (using
mubiomics). Demultiplexed reads were aligned to the bacterial
reference library - a vaginal microbiome reference library
available from http://microbiome.fhcrc.org/apps/refpkg/, con-
taining 633 sequences, representing 138 bacterial taxa, using
pyNAST. The aligned sequences were then mapped to their
bacteria of origin using the classification algorithm pplacer [22]
and visualized using R-scripts that were developed at Einstein [18]
(see Statistical Analyses section).
E. coli Inhibitory Activity
Spent culture supernatants (SCS) from L. crispatus (ATCC
33197, M35, SJ-3C, and 60), L. iners (DSM 13335, UPII 60B-BEI
HM-131, and 143D-BEI HM-126), and G. vaginalis (ATCC 49145,
14018) were prepared by centrifuging overnight cultures of
bacteria at 2000 g for 15 min at room temperature and then
filtering the supernatant to remove bacteria and particulate matter
(0.22 mm syringe filter). L. crispatus strains were grown in MRS
broth; L. iners in 1% proteose peptone, 1% beef extract, 0.5% yeast
extract, 86 mM NaCl, 0.8 mM MgSO4, 0.3 mM MnSO4,
11.5 mM K2HPO4, 10% fetal bovine serum, and 2% glucose;
and G. vaginalis in brain heart infusion broth supplemented with
10% FBS and 5% Fildes enrichment. The SCS from each of these
cultures and their respective growth media were serially diluted in
normal saline and then incubated with E. coli (ATCC strain 43827)
(,109 cfu/mL) for 2 h at 37uC. The mixtures were then further
diluted in saline (to yield 800–1000 E. coli colonies on control
plates) and plated on agar enriched with trypticase soy broth [15].
Colonies were counted using ImageQuant TL v2005 after an
overnight incubation at 37uC. To control for differences in cfu of
the L. crispatus, L. iners or G. vaginalis cultures, the inhibitory activity
was normalized to lowest bacterial yield in a post-hoc analysis or,
alternatively, the SCS were diluted based on different yields prior
to incubating them with E. coli. All samples were tested in
duplicate and the percentage inhibition was determined relative to
the colonies formed on culture media control plates.
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Statistical Analyses
E. coli inhibitory activity was dichotomized as .90% (high) and
,20% (low). Categorical variables were compared between groups
by Chi-square or Fisher’s exact test. Continuous variables were
compared by the Student t test or the Mann-Whitney U test,
depending on the distribution of the data. Clinical data were
analyzed using STATA (v11.0; StataCorp, Inc., College Station,
TX). All plotting and statistical comparisons for NGS were
performed in R v2.12.2 using a script developed in-house
(available upon request). The pairwise Kantorovich-Rubinstein
(KR) distances (equivalent to the weighted UniFrac distance [23]
between samples were calculated with p=1 and normalized with
respect to the diameter of the reference tree. Principal component
analysis was performed to determine differences between preg-
nancy and the microbiome and dichotomized E. coli inhibitory
activity and the microbiome. Using a conservative approach, the
PERMANOVA analysis was performed on the Kantorovich-
Rubinstein (KR) distances between sample microbiomes, with
pregnancy and E. coli inhibitory activity as the factors, respectively.
Fisher’s exact tests were performed with pregnancy status and E.
coli inhibitory activity as binary factors against the dominant
bacterial taxon. Shannon and Simpson diversity indices were
calculated to determine significant differences in diversity between
pregnant and non-pregnant samples and samples with high and
low E. coli inhibitory activity. To ensure that sufficient sampling of
the microbiome had occurred, a rarefaction analysis was
performed. Bacterial taxa were grouped to reflect healthy
lactobacilli (group 1), intermediate bacteria (at times associated
with BV diagnosed by Nugent’s score [24], group 2) and
pathogenic bacteria (groups 3 and 4): Group 1: L. crispatus, L.
jensenii, and L. gasseri, Group 2: L. iners, Group 3: G. vaginalis,
Sneathia Sanguinegens, BVAB1, BVAB2, Megasphaera, Prevotella bivia,
Prevotella melaninogenica, Prevotella genogroup 1 and genogroup 2,
and Atopobium vaginae, and Group 4: Streptococcus anginosus and
Staphylococcus hominis. Principal component analyses were per-
formed using Group 1, Group 3, and Group 4 to reduce the
dimensions of the data. Spearman correlation coefficients (SCC)
were used to examine correlations between bacterial groups and
soluble immune mediators measured in the parent study [12]. The
following mediators were included in the analysis: secretory
leukocyte protease inhibitor (SLPI), human neutrophil peptide
1–3 (HNP1–3), human beta defensin (HBD)-1, HBD-2, and HBD-
3, and cytokines/chemokines including interleukin (IL)-1a, IL-1b,
IL-1 receptor antagonist (IL-1ra), IL-6, IL-8, macrophage
inhibitory protein (MIP)-1a, MIP-1b, and regulated on activation,
normal T-cell expressed and secreted (RANTES). All tests were
two-sided with p value of ,0.05 considered statistically significant.
Table 1. Demographic and clinical characteristics of women with low and high E. coli inhibitory activity.
Low E. coli inhibitory
activitya (n =6)
High E. coli inhibitory
activityb (n=10) p-valuec
Age, median (range) 24 (22–41) 26.5 (22–31) 0.30
Race, n (%) 0.70
White 5 (83) 8 (80)
Black 1 (17) 1 (10)
Other 0 1 (10)
Pregnant 1.0
No 3 (50) 5 (50)
Yes 3 (50) 5 (50)
Current Smoker, n (%) 1 (17) 0 0.38
History of genital herpes, n (%) 0 2 (20) 0.50
History of chlamydia, n (%) 1 (17) 1 (10) 1.0
History of gonorrhea, n (%) 0 0 1.0
History of genital warts, n (%) 1 (17) 0 0.38
Contraception, n (%) 1.0
None 4 (67) 9 (90)
Barrier Methods 0 0
Oral contraceptive pills 0 1 (10)
Intra-vaginal ring 0 0
Progesterone injectable 1 (17) 0
Progestin-containing IUD 1 (17) 0
Lateral vaginal wall pH, median (range) 4.9 (4.6–5.2) 4.6 (4.2–5.5) 0.31
Method of swab collection, n (%) 0.45
Physician-collection 3 (50) 5 (50)
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Results
Description of Participants
Sixteen of the 20 subjects had paired-end reads that were
sufficient to characterize the microbiome. The characteristics of
these subjects are summarized in Table 1 grouped according to E.
coli inhibitory activity (10 with high activity and 6 with low
activity). The two groups did not differ with respect to age, race,
number of pregnant women, current smoking status, history of
prior sexually transmitted infections (STI), contraceptive use,
Figure 1. High E. coli inhibitory activity is associated with L. crispatus predominant microbiome. Heat Map of community compositions
and proportional abundances of bacteria. The first row of colored tiles indicates the level of E. coli inhibitory activity (claret =.90% inhibition and
blue ,20% inhibition). Each subsequent row represents the bacterial taxon and its proportional abundance (on a base 10 logarithmic scale). A taxon
is only shown if$217 reads were assigned there for any sample (corresponding to retaining all reads above the 90th percentile). The Roman numerals
at the bottom of the figure correspond to vaginal microbiome groups as reported by Ravel et al. The last 3 samples have not been classified do to
limited sample size in this region of the dendogram.
doi:10.1371/journal.pone.0096659.g001
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method of vaginal swab collection (physician or self-collected), or
vaginal wall pH (Table 1).
Microbiome Analysis
NGS produced 9,111,237 high quality, non-chimeric, joined,
paired-end reads, of which 8,946,862 were successfully assigned a
bacterial identity. Those that could not be aligned (and therefore
assigned) were of non-bacterial origin. Less than 2% of the reads
were determined to be chimeric and were therefore removed. The
short reads were submitted to the NCBI Short-Read Archive
(Submission ID: SRP034665).
Community compositions and proportional abundances of
bacteria are shown in the heat map of Figure 1. All but one of
the samples (JG46) was dominated by Lactobacillus species
including L. crispatus and L. iners, which is consistent with the
absence of clinical BV in the cohorts. Most strikingly, the majority
of samples with high E. coli inhibitory activity were dominated by
L. crispatus, while those with low activity were dominated by L.
iners. The two exceptions were JG46 and JG50, which had a
microbiome dominated by Atopobium vaginae and Lactobacillus gasseri,
respectively; both samples were in the low E. coli inhibitory activity
cohort. The microbiome communities found in the samples
clustered into three groups: L. crispatus, L. iners, and L. gasseri and
are consistent with the community types found by Ravel et al. [6]
A rarefaction plot is a standard analysis used to evaluate whether
sufficient reads have been tested to detect species richness. If the
gradient of the rarefaction curve decreases sharply after some level
of species richness, it is a good indication that increasing the read
depth would discover only the very rarest of species. Due to the
low gradient of the curves of the rarefaction analysis at the read
depth at which the clinical samples were sequenced, only the rarest
of bacteria are likely to have been missed from our analyses (data
not shown).
High E. coli inhibitory activity was predictive of an L. crispatus
dominated microbiome (Fisher’s exact test, p value = 0.007), while
low activity was not significantly associated with any dominant
bacterial taxon. Furthermore, the vaginal microbiome in women
with high E. coli inhibitory activity were significantly different than
women with low activity by principal component analysis
(p = 0.001, Figure 2A). However, there were no differences
between the pregnant and non-pregnant women (Figure 2B) and
no association was found between pregnancy and any of the
dominant bacterial taxa. Furthermore, we found no significant
association between age, race, vaginal wall pH and L. crispatus
predominance. There was also no difference in bacterial diversity
between pregnant and non-pregnant women or between those
with high or low E. coli inhibitory activity using Shannon and
Simpson diversity indices (not shown).
In the parent study, the concentrations of protein and a subset
of cytokines, chemokines, defensins and antimicrobial peptides
were measured in the vaginal swab supernatants and SLPI, HBD-
1, HBD-2, IL-1b, IL-6, and IL-8 correlated modestly with E. coli
inhibitory activity among non-pregnant, but not pregnant women
[12]. To assess whether any of these mediators were associated
with the bacterial groups, Spearman correlation coefficients were
measured. None of the bacterial groups correlated with the soluble
immune mediators.
Spent Culture Supernatants from L. crispatus have
Significant E. coli Inhibitory Activity
To gain further insight into the link between the microbiome
composition and E. coli inhibitory activity, SCS from L. crispatus, L.
iners, and G. vaginalis were tested for the ability to inhibit E. coli
relative to the growth media for each bacteria. The bacterial yields
of the cultures used to produce the SCS were as follows: L. crispatus
33197: 2.56109 cfu/mL; L. iners ARL1 (13335): 4.26108 cfu/mL;
Figure 2. The microbiome associated with high E. coli inhibitory activity is significantly different than the microbiome in women
with low activity (p=0.042). The pairwise Kantorovich-Rubinstein (KR) distances between sample microbiomes were calculated and a
PERMANOVA principal component analysis was performed with E. coli inhibitory activity (A) and pregnancy (B) as the factors. The two axes represent
the first two principal components of the pairwise KR distance matrix. The red point demarks the group centroid, while the black open points
represent the sample coordinates in the first two principal components. The p-value test statistic is displayed at the top of each plot area, indicating
the statistical significance of the difference in variances when samples were grouped according to the factor (i.e., E. coli inhibitory activity or
pregnancy). The Eigen values, or the amount of variation in the data accounted for by each principal component, are found in parentheses adjacent
to PC1 and PC2.
doi:10.1371/journal.pone.0096659.g002
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L. iners 60B: 1.06109 cfu/mL; L. iners 143D: 6.56108 cfu/mL; G.
vaginalis 49145: 4.56108 cfu/mL; G. vaginalis 14018:1.06109 cfu/
mL. When the SCS were diluted 1:10 prior to mixing with E. coli,
L. crispatus 33197 showed the greatest magnitude of inhibitory
activity and reduced the E. coli cfu by greater than 1 log after
adjusting for differences in bacterial yields, although SCS from L.
iners 60B and G. vaginalis 14018 also showed significant inhibitory
activity (p,0.05) (Figure 3a). To further explore the inhibitory
activity of L. crispatus, we tested serial dilutions of 3 additional
strains (after diluting the SCS to adjust for differences in bacterial
yields as follows: L. crispatus M35: 4.16108 cfu/mL; L. crispatus SJ-
3C: 1.36108 cfu/mL; and L. crispatus 60: 26107 cfu/mL). L.
crispatus 60 displayed the most potent activity and retained
significant activity even after dilution of 1:25 (Figure 3b).
Discussion
The current study demonstrates that a L. crispatus dominant
vaginal microbiome community is associated with E. coli inhibitory
activity and supports the contention that the microbiome
contributes to host defense. This notion is further supported by
the finding that culture supernatants from L. crispatus had the most
potent inhibitory activity, although the activity varied between
different strains. The results are consistent with prior observations
that E. coli inhibitory activity is reduced in the setting of BV, a
dysbiotic condition associated with loss of L. crispatus [6,7] and with
a small proteomic study showing that Lactobacillus proteins (three
originally described as proteins of L. crispatus and one of L. jensenii)
were present exclusively in CVL samples with high but not in
samples with low E. coli inhibitory activity [15]. While the
microbiome from women with high E. coli inhibitory activity was
dominated by L. crispatus, women with low activity (even in the
absence of clinical BV) had a trend towards L. iners dominance.
However, we did not observe any significant increase in bacterial
diversity in samples from women with low E. coli inhibitory
activity. It is possible that the other common healthy Lactobacillus
species such as L. jensenii, also contribute to E. coli inhibitory activity.
L. jensenii was one of the more prevalent bacteria in the women
with high activity (Figure 1).
There were no differences detected in the vaginal microbiome
between healthy near term pregnant and non-pregnant women.
These findings are consistent with one other study in which the
microbiome exhibited less diversity and richness in pregnant
women sampled between 18–32 weeks gestation, but returned to
the non-pregnant community structure in late gestation (.32
weeks) [16]. Both studies focused on healthy women, the majority
of whom delivered at term. Larger studies in women at risk for
preterm birth are needed to determine whether changes in the
Figure 3. L. crispatus culture supernatants inhibit E. coli. (a) Bar graphs depicting the E. coli cfu/ml after overnight incubation with 1:10 dilution
in normal saline of culture supernatants obtained from the indicated bacterial species or respective control media. The results were adjusted for
differences in colony counts of the bacteria from which SCS were obtained and are presented as mean 6 SD obtained from 3 independent
experiments. (b) The spent culture supernatants obtained from three additional strains of L. crispatus (M35, SJ-3C, and 60) were normalized by
diluting in culture media to that of the lowest growth (26107 cfu/ml) and then serial dilutions (neat, 1:5, 1:10 and 1:25) were mixed with E. coli and
tested for inhibitory activity. Results are mean 6 SD from duplicate plates. The number symbol indicates that no bacterial colonies were observed on
plates after incubation with undiluted L. crispatus 60 SCS. The asterisks represent a significant reduction in E. coli cfu relative to its control growth
media (p,0.01).
doi:10.1371/journal.pone.0096659.g003
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vaginal microbiome and/or E. coli inhibitory activity will provide a
biomarker of risk for adverse outcomes including E. coli
colonization and associated sequelae (e.g. chorioamnionitis and
neonatal sepsis).
The potential utility of E. coli inhibitory activity as a biomarker
of mucosal health, however, may differ in populations where
lactobacilli species are not the dominant microflora. This notion is
supported by two small sub-studies of African women who were at
high-risk for HIV acquisition [25]. In the latter studies, having
higher E. coli inhibitory activity was associated with an increased
risk of HIV acquisition and, in one study, with a higher viral set
point [26]. However, the participants in these studies had
relatively high Nugent scores and lower median E. coli inhibitory
activity (50% inhibition) compared to that observed in the healthy
U.S cohorts (.70% inhibition). Moreover, in the HIV serocon-
verters, E. coli inhibitory activity correlated with the concentrations
of several pro-inflammatory cytokines and chemokines, suggesting
that the activity may be a biomarker of inflammation in high-risk
women. In contrast, in the current study, there were no significant
correlations between concentrations of mucosal immune media-
tors and the bacterial groups further indicating that perhaps host
immune factors contribute little to this antimicrobial activity in
populations where the microbiome is typically dominated by
protective Lactobacillus species. Thus, in populations where there is
a relative paucity of protective lactobacilli (e.g. high risk African
cohorts), E. coli inhibitory activity may be more influenced by
inflammatory molecules and serve as a biomarker of HIV risk,
whereas in populations where L. crispatus is common, high activity
may be representative of a healthy vaginal microbiome.
A limitation of this exploratory study is the small sample size.
Thus, as noted above, we cannot preclude a broader association
with other healthy Lactobacillus species. Furthermore, conclusions
about the effect of race, ethnicity, age, pH, contraceptive use and
host immune mediators on the vaginal microbiome should be
made with caution. Another study limitation is that we did not
confirm sexual abstinence. Finally, differences in the inhibitory
activity of bacterial SCS may be impacted by differences in the
bacterial yields from which supernatants were obtained. In an
effort to account for this difference, we adjusted the E. coli cfu by
the bacterial cfu/mL used to produce the SCS in a post hoc
analysis (Figure 3a) or adjusted the SCS by dilution prior to
incubating the samples with E. coli (Figure 3b).
The current study highlights the possibility that E. coli inhibitory
activity may be a functional feature of a Lactobacillus crispatus
dominant healthy vaginal microbiome. In addition to studies with
larger more diverse cohorts, future studies should also include
proteomic and metabolomic analyses on the sample to further
define the nature and origin (host and/or microbiome) of the
molecules that contribute to the E. coli inhibitory activity. A
longitudinal study in pregnancy is ongoing and will help to
elucidate whether high inhibitory activity against E. coli translates
to a reduction in sub-clinical or overt genital tract infection and
preterm birth. These findings could promote the identification of
novel strategies to enhance the antimicrobial activity of genital
tract secretions. Further studies are needed to determine if
introducing lactobacilli derived molecules or sustaining a L.
crispatus dominant microbiome may promote a healthy vaginal
environment. These approaches could lead to reduced risk of
bacterial vaginosis, chorioamnionitis, preterm birth and perinatal
infection and be used as a safer alternative to traditional antibiotics
[27].
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